Resistance to <scp>Bruton tyrosine kinase</scp> inhibition in <scp>chronic lymphocytic leukaemia</scp> and <scp>non‐Hodgkin</scp> lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

Published:2022-08-27 Issue:2 Volume:200 Page:137-149
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nakhoda Shazia¹^ORCID,Vistarop Aldana²³,Wang Y. Lynn²³^ORCID

Affiliation:

1. Department of Hematology Fox Chase Cancer Center Philadelphia Pennsylvania USA

2. Department of Pathology Fox Chase Cancer Center Philadelphia Pennsylvania USA

3. Blood Cell Development and Function Program Fox Chase Cancer Center Philadelphia Pennsylvania USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18418

Reference126 articles.

1. Bruton's Tyrosine Kinase Links the B Cell Receptor to Nuclear Factor κb Activation

2. Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement

3. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

4. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

5. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus;International Immunopharmacology;2024-12

2. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo;European Journal of Medicinal Chemistry;2024-11

3. A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma;Scientific Reports;2024-09-11

4. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

5. Drug resistance in human cancers — Mechanisms and implications;Life Sciences;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3